



Febrile reaction after hematopoietic stem cell infusion is more frequent 
if no steroid premedicaton is given which results in more frequent use 
of antibiotics in early post-transplant phase
Febrilne reakcije nakon infuzije krvotvornih matičnih stanica češće su ukoliko se ne 
primijeni premedikacija kortikosteroidima što rezultira većom upotrebom antibiotika 
rano nakon transplantacije
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Summary
Background: There is no consensus as to the need for steroid premedication before fresh product hematopoietic 
stem cell (HSC) infusion. In case of febrile reaction post-HSC infusion, on-call staff frequently prescribe antibiotics 
empirically. Considering the recent data on the value of microbiota and its influence on GVHD incidence, we 
analysed the frequency of febrile reactions and the use of antibiotic after HSC infusion in 149 consecutive patients.
Methods: In the time period between 1/2018 and 10/2019, 149 patients were subject to transplantation in our 
institution. Per institutional standard operating procedure (SOP), all the patients received premedication before 
hematopoietic stem cell infusion consisting of 20 mg chloropyramine-chlorid iv, and in case of ABO incompatible 
graft 1 mg/kg methylprednisolone iv. Retrospective data was collected by using patient charts. Survival probabil-
ity was calculated by applying Kaplan-Meier method.
Results: Fifty-two patients received steroids, 12 patients (23%) developing fever after graft infusion, 46 patients 
received no steroids, 26 of them (57%) developed fever (p<0.001). There was no difference in the number of patients 
having positive blood cultures. Nine (17%) and 16 (35%) patients received IV antibiotics in the „steroid” and no-ster-
oid” group, respectively (p<0.05). There was no difference in survival between „steroid” and „no-steroid” group.
Conclusions: Even with no difference in the frequency of febrile episodes caused by systemic infection, a significantly 
more patients not receiving steroid premedication develop fever and are treated with IV antibiotics, which could poten-
tially have further implications on transplantation outcomes due to its influence on microbiota early post-transplant.
Sažetak
Uvod: Trenutno ne postoji konsenzus o potrebi primjene premedikacije kortikosteroidima prije infuzije svježih 
krvotvornih matičnih stanica (KMS). U slučaju febrilne reakcije nakon infuzije KMS-a, dežurno osoblje često pro-
piše antibiotike empirijski. Uzimajući u obzir nedavne podatke o vrijednosti mikrobiote i njezinom utjecaju na 
incidenciju GVHD-a, analizirali smo učestalost febrilnih reakcija i uporabu antibiotika nakon infuzije KMS-a u 149 
uzastopna bolesnika.
Metode: U razdoblju između 1/2018. i 10/2019. u našoj je ustanovi transplantirano ukupno 149 pacijenata. 
Prema institucionalnom standardnom operativnom postupku (SOP), svi su pacijenti primali premedikaciju prije 
infuzije krvotvornih matičnih stanica koja se sastojala od 20 mg kloropiramin-klorida iv, a u slučaju ABO inkompa-
tibilnog presatka i 1 mg / kg metilprednizolona iv. Retrospektivno su prikupljeni podaci koristeći povijesti bolesti 
pacijenata. Vjerojatnost preživljavanja izračunata je Kaplan-Meierovom metodom.
Rezultati: Pedeset i dva bolesnika su primila kortikosteroide, od njih je 12 bolesnika (23%) razvilo vrućicu nakon 
infuzije presatka, dok 46 bolesnika nije primilo kortikosteroide, a od njih je 26 (57%) razvilo vrućicu (p <0,001). 
Nije bilo razlike u broju bolesnika koji su imali pozitivne hemokulture. U skupini koja je primila kortikosteroide, 9 
(17%) bolesnika je liječeno iv antibioticima, dok je u skupini koja nije primala kortikosteroide, 16 (35%) bolesnika 
liječeno iv antibioticima (p <0,05). Nije bilo razlike u preživljenju između te dvije skupine.
Zaključci: Čak i bez razlike u učestalosti febrilnih epizoda uzrokovanih sistemskom infekcijom, znatno više paci-
jenata koji nisu dobili premedikaciju je razvilo vrućicu i liječilo se iv antibioticima, što bi potencijalno moglo imati 
daljnje implikacije na ishode transplantacije zbog utjecaja na mikrobiotu rano nakon transplantacije.
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Given that, our institutional SOP warrants steroids to 
be given in case of ABO incompatible graft infusion. 
However, in case of febrile reaction, happening usual-
ly when steroids are not given as a premedication, on 
call staff frequently prescribes antibiotics along with 
antipyretics, given that these patients are often already 
neutropenic and systemic infection as cause of febrile 
reaction cannot be excluded. This results in patient be-
ing treated with broad-spectrum antibiotics from day 
0 until neutrophil recovery, usually more than 14 days. 
After allo-HSCT, intestinal bacteria modulate risks of 
infection and GVHD[5] and several studies have shown 
that treatment with antibiotics with increased activity 
against anaerobes correlates with increased graft ver-
sus host disease (GVHD) related mortality and altered 
intestinal microbiota in allogeneic hematopoietic stem 
cell transplantation (allo-HSCT) patients with fever[6,7]. 
Empiric antibiotics given in patients with febrile re-
action, such as piperacillin-tazobactam and imipen-
em-cilastatin, target intestinal anaerobes that can be 
potent modulators of the severity of GVHD[8]. Other 
major problem with empiric antibiotics disturbing the 
normal intestinal flora is the facilitation of bacterial 
overgrowth with emergence of resistant microorgan-
isms[9]. These organisms themselves can cause serious 
infections, but they will also encourage the transfer of 
resistance factors to other bacteria. The broader spec-
trum of an agent, the more effect it shall have on the 
intestinal flora[9].
 The aim of this study was to examine how premed-
ication practice influences the use of antibiotics ear-
ly on after HSCT. For this purpose, we analysed the 
premedication use, frequency of febrile reactions and 
the use of antibiotics after HSC infusion in 149 con-
secutive patients being treated in the Division of Hae-
matology of the University Hospital Centre Zagreb, 




 We conducted a single-centre retrospective study 
of consecutive patients who underwent allo-HSCT in 
our institution. The study included 149 patients trans-
planted in the University Hospital Centre Zagreb, Cro-
atia between January 2018 and November 2019. Data 
was extracted from patient charts and electronic pa-
tient records using hospital information system.
 Per institutional standard operating procedure (SOP), 
prior to stem cell infusion all patients received pre-
medication consisting of 20 mg chloropyramine-chlo-
ride intravenously (IV). In case of ABO incompatible 
graft, the patients received additional 1 mg/kg methyl-
Introduction
 Hematopoietic stem cell transplantation (HSCT) 
is a curative treatment option for many hematological 
malignancies, as well as non-malignant disorders. The 
number of HSCT worldwide is increasing every year, 
with now alternative donor options such as haploi-
dentical HSCT emerging, as well as emergence of new 
conditioning, assuring that more wide population of 
patients, like elderly and patients with comorbidities, 
can be considered for this treatment option[1]. HSC 
grafts required for this procedure can be obtained 
from umbilical cord blood, bone marrow or periph-
eral blood of a related or unrelated donor. Depending 
on their source, the grafts contain varying quantities 
of donor red blood cells that can potentially be bound 
and destroyed by conjugate blood group antibodies 
produced by the recipient immune system, as well as 
varying titres of anti-ABO antibodies that can lyse 
recipient erythrocytes after transplantation, resulting 
in acute haemolytic transfusion reaction. Apart from 
acute hemolysis upon transplantation, major compli-
cations of major ABO-incompatible transplantation 
include also delayed red cell engraftment and develop-
ment of pure red cell aplasia (PRCA).[2]
 Still, unlike solid organ transplantation, in HSCT 
ABO incompatibility is not considered a barrier for 
selection, such as HLA mismatch is, even though clin-
ical outcomes of ABO-incompatible grafts are gener-
ally considered inferior to those in ABO-compatible 
HSC, and ABO-incompatibility can have influence in 
engraftment, Graft-versus-host disease (GVHD) de-
velopment and overall survival.[3]
 ABO incompatibility has three features: major in-
compatibility, that occurs when the recipient with O 
blood group receives graft from A/B/AB donor, minor 
incompatibility which occurs when the donor with 
anti A/B antibodies donates stem cells to a patient 
with A/B or AB blood group and bidirectional incom-
patibility is defined when both donor and recipient 
have anti ABO antibodies[2]. Haemolytic reaction that 
occurs in ABO incompatible transplants can cause, 
among many other things, a febrile reaction. To avoid 
or weaken hemolytic reaction, premedication contain-
ing diphenhydramine ± IV steroids can be given prior 
to stem cell infusion. Whether premedication is given 
or not is specific for each institution and the need for 
it can be determined by donor-recipient HLA dispar-
ity, source of cells (bone marrow or peripheral blood) 
and graft manipulation[4]. Most centres would avoid 
IV steroids as a premedication, at least in ABO com-
patible transplants. Also, if bone marrow is used as 
graft source, it contains much more erythrocytes than 
grafts collected from peripheral blood, even after graft 
manipulation and erythrocyte depletion procedure. 
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Table 1. Patient and transplant characteristics
Tablica 1. Karakteristike pacijenata i transplantacije
Patient and transplant characteristic N=149





Acute myeloid leukemia 72 (48)
Myelodysplastic syndrome 19 (13)
Acute lymphoblastic leukemia 24 (29)
Aplastic anemia 6 (4)
Chronic myelofibrosis 6 (4)
Hodgkin lymphoma 9 (6)
Non-Hodgkin lymphoma 7 (5)
Chronic myeloid leukemia 2 (1)
Multiple myeloma 2 (1)
Fanconi anemia 1 (0.6)










matched unrelated 95 (64)




no steroid 46 (30)
Patients receiving IV antibiotics prior 
to day 0 (excluded from analysis) 51 (34.1 )
MAC- myeloablative conditioning; RIC- reduced intensity conditioning
Incidence of fever and subsequent IV antibiotic 
use in „steroid” and „no-steroid” group
 Fifty-one patients (34.1%) received antibiotic treat-
ment prior to day 0 and were excluded from further 
analysis which was subsequently done on 98 remain-
prednisolone IV as premedication. Temperature was 
measured every 2 h and in case of elevation in body 
temperature to higher than 38.1 °C blood cultures 
were drawn. Antibiotic therapy was introduced per 
physician’s indication.
 Fever was defined as a single axillary temperature-
measurement ≥38.3 °C or at least 2 measurements 
of ≥38.0 °C, at least for 1 h apart at any time during 
24h after stem cell infusion was finished. At first rec-
ognition of fever, a minimum of two blood cultures 
(one through the central catheter) were drawn, a urine 
culture, a chest X-ray, and other tests as clinically in-
dicated were performed. Antibiotic therapy with pip-
eracillin/tazobactam was initiated per physician`s 
indication. Acetaminophen was allowed as needed to 
achieve symptomatic relief.
 Minor ABO incompatibility was defined as a pas-
sive transfer of incompatible blood group antibodies 
from the donor to the recipient (e.g. from a type O do-
nor to a type A, type B, or type AB recipient). Major 
ABO incompatibility was defined as the presence of 
anti-donor blood group antibodies in recipient plasma 
(e.g. from a type A, type AB, or type B donor to a type 
O recipient). Bi-directional ABO incompatibility was 
defined as the presence of both major and minor in-
compatibilities (e.g. type A donor to a type B recipient).
Statistical Analysis
 Demographic, clinical and laboratory data analyz-
ed are presented descriptively. χ2 was used for com-
parison of two groups, p <0.05 was considered statis-
tically significant. The probability of OS was estimated 
using the Kaplan–Meier method.
Results
Patients' and transplantation characteristics
 Patients' and transplantation characteristics are 
described in Table 1. In the given time period, 72 fe-
male and 77 male patients with median age of 48 years 
(range 3-70) underwent hematopoietic stem cell trans-
plantation. The majority of patients had AML (n=72, 
48%), 19 (13%) MDS, 24 (29%) ALL, 6 (4%) AA, 6 
(4%) OMF, 9 (6%) HL, 7 (5%) NHL, 2 (1%) CML, 2 
(1%) MM, 1 Fanconi anemia and 1 HLH. Ninety-five 
patients (64%) received graft from a matched unrelat-
ed donor, 30 (20%) from matched related donor and 
24 (16%) from haploidentical related donor. Most of 
the patients (63%) received a reduced intensity condi-
tioning and 37% of them received myeloablative con-
ditioning. A total of 72 (48%) patients were ABO com-
patible, while 22 (15%) had major, 38 (26%) minor and 
17 (11%) bi-directional ABO incompatibility.
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Discussion
 The objective of this study was to assess how ster-
oids used as part of premedication before HSC trans-
fusion influence the appearance of febrile reactions 
and subsequent broad-spectrum IV antibiotic use. We 
have showed that avoidance of the use of steroids re-
sults in the rise of febrile reactions in recipients of HSC 
grafts, and increased use of broad-spectrum antibiotic. 
The use of broad-spectrum antibiotics was noted, even 
though there was no significant difference in bacter-
emia between groups.
 The infusion of HSC grafts, particularly ABO in-
compatible ones, can lead to many undesired side-ef-
fects, and febrile reaction is one of them. Febrile reac-
tion can occur as a part of acute hemolytic reaction in 
ABO incompatible graft infusion.[10] However, febrile 
reaction can also occur in ABO compatible graft in-
fusion, possibly as a reflection of immunological reac-
tions similar to ones described in febrile non-hemolyt-
ic transfusion reactions, caused by pro-inflammatory 
cytokines or recipient antibodies encountering donor 
antigen in the blood product.[11] Immunological reac-
tion and subsequent cytokine release as a part of cy-
ing patients. The total of fifty-two patients (53%) re-
ceived steroids as a premedication („steroid” group), 
and from that group 12 patients (23%) developed fe-
ver after graft infusion, while in the group of 46 pa-
tients (47%) that did not receive steroids („no-steroid” 
group) prior to graft infusion, 26 of them (57%) devel-
oped fever (p<0.001) (Figure 1). In the „steroid” group, 
9 (17%) patients had received IV antibiotics as op-
posed to „no-steroid” group, where 16 of them (35%) 
received IV antibiotics (p<0.05) (Figure 2). There was 
no difference in the number of patients that had pos-
itive blood cultures within 24h of graft infusion; in 
„steroid” group there were 3 (6%) and in „no-steroid” 
group 4 (7%) such patients (p=0.27) (Figure 3).
 Analysis of overall survival showed no difference 
in the survival between patients receiving steroids as 
premedication and patients receiving no steroids, the 
curves are practically overlapping (Fig 2.A). No signif-
icant difference was found when we compared patients 
developing fever on day 0 to patients that remained 
afebrile, as well as when we compared patients who 
started with IV antibiotics on day 0 to ones that did 
not (Fig 2.B. and 2.C).
Figure 1. Influence of premedication on A. fever appearance on day 0 and B. IV antibiotic use initiation on day 0; C. 
Incidence of positive blood cultures within 24h of graft infusion.
Slika 1. Utjecaj premedikacije na pojavu A. vrućice na dan 0 i B. početak upotrebe IV antibiotika na dan 0; C. učestalost 
pozitivnih hemokultura unutar 24 sata od infuzije presatka.
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Early use of broad-spectrum antibiotic therapy comes 
not without a negative effect. It particularly applies to 
antibiotics with increased activity against anaerobes as 
studies have shown that their use correlates with in-
creased graft versus host disease (GVHD) related mor-
tality and altered intestinal microbiota in allogeneic 
hematopoietic stem cell transplantation (allo-HSCT) 
patients with fever[6]. After allo-HSCT, intestinal bac-
teria modulate risks of infection and GVHD. Empiric 
antibiotics given in patients with febrile reaction, such 
as piperacillin-tazobactam and imipenem-cilastatin, 
target intestinal anaerobes that can be potent modula-
tors of the severity of GVHD[8]. Other major problem 
with empiric antibiotics disturbing the normal intes-
tinal flora is the facilitation of bacterial overgrowth 
with emergence of resistant microorganisms[9]. These 
organisms themselves can cause serious infections, 
but they will also encourage the transfer of resistance 
factors to other bacteria. The broader spectrum of an 
agent, the more effect it shall have on the intestinal 
flora[9]. Considering all that, and also the fact that the 
febrile reactions are often not caused by a systemic in-
fection, the antibiotics use should be reduced. Howev-
tokine release syndrome (CRS) are hypothesized to 
be the cause for noticed high fevers in considerable 
portion of patients after HSC transplantation using 
peripheral blood stem cells from haploidentical do-
nors.[12,13] It was hypothesized that the fever was likely 
a cytokine-mediated phenomenon associated either 
with initial proliferation of alloreactive T cells or from 
the actual destruction of alloreactive T cells by PTCy 
given per protocol on days +3 and +4.
 To avoid or weaken this haemolytic reaction, pre-
medication such as diphenhydramine 30-50 mg IV/p.o. 
is given prior to stem cell infusion, and some centres, 
including ours, add steroids to premedication protocol 
in order to dampen the haemolytic reaction in ABO 
incompatible graft infusion. The occurrence of fever 
in these patients frequently calls for broad-spectrum 
antibiotic therapy initiation. The patients are usually 
neutropenic at that point in time and evaluating acute 
phase reactants such as CRP and procalcitonin is of 
little value as they tend to rise with any kind of immu-
nological reaction post-transplant[14], as well as with 
use of certain drugs, like anti-T cell antibody therapy, 
often used pre-transplant.[15]
Figure 2. Overall survival according to A. steroid use in premedication; B. febrile state on day 0 (p=NS); C. initiation 
of antibiotic therapy on day 0 (p=NS)
Slika 2. Ukupno preživljenje prema A. upotrebi kortikosteroida u premedikaciji; B. vrućice na dan 0 (p = NS); C. početak 
antibiotske terapije nultog dana (p = NS)
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er, it is a hard decision not to start IV antibiotics, if a 
patient is having a fever and chills, and CRP is on the 
rise. We believe that this study has shown that addition 
of steroids to the premedication protocol can prevent 
the occurrence of febrile reaction and thereby decrease 
the use of antibiotics early on and relieve physicians 
in charge of making such difficult decisions. In our 
study we did not show survival benefit, possibly due 
to too low patient number. Certainly, this kind of anal-
ysis should definitely be performed in a larger patient 
number in order to show significant impact on surviv-
al, if any. Also, the analysis of influence of premedica-
tion practice on GVHD incidence is lacking, for which 
also a bigger cohort of patients would be needed in or-
der to show significant difference due to relatively low 
incidence of intestinal GVHD.
Conclusion
 This analysis showed that even though there is no 
difference in the frequency of febrile episodes caused 
by a systemic infection, significantly more patients 
that did not receive steroid as a part of premedica-
tion protocol develop fever and are treated with IV 
antibiotics. The use of antibiotics in early post-trans-
plant phase without real need could potentially have 
further implications due to its influence on microbi-
ota, as well as MDR strain selection. Adding steroids 
to premedication protocols could allow physicians to 
avoid early broad-spectrum antibiotics use in this pa-
tient population.
REFERENCES
 [1] Passweg JR, Baldomero H, Chabannon C, et al. The EBMT 
activity survey on hematopoietic-cell transplantation and cel-
lular therapy 2018: CAR-T's come into focus. Bone Marrow 
Transplant. 2020; 55(8):1604-1613.
 [2] Vaezi M, Dameshghi DO, Souri M, Setarehdan SA, Alimo-
ghaddam K, Ghavamzadeh A. ABO Incompatibility and He-
matopoietic Stem Cell Transplantation Outcomes. Int J Hema-
tol Oncol Stem Cell Res. 2017; 11(2): 139-147.
 [3] Booth GS, Gehrie EA, Bolan CD, Savani BN. Clinical Guide to 
ABO-Incompatible Allogeneic Stem Cell Transplantation. Biol 
Blood Marrow Transplant. 2013;19 (8): 1152-1158.
